. Author manuscript; available in PMC: 2018 Jun 1.

Published in final edited form as: Mov Disord. 2017 Apr 3;32(6):913–917. doi: 10.1002/mds.27006

Table 1.

The association between prior use of cholesterol-lowering drugs and Parkinson’s disease.

Type of cholesterol lowering drugs	Controls N (%)	PD cases N (%)	Multivariable logistic regression model
Type of cholesterol lowering drugs	Controls N (%)	PD cases N (%)	aOR^*	95% CI		P-value
Lipophilic only	375 (16.2%)	507 (21.8%)	1.58	1.33	1.89	<0.0001
Hydrophilic only	100 (4.3%)	105(4.5%)	1.19	0.88	1.61	0.25
Both statins	75 (3.2%)	104 (4.5%)	1.61	1.17	2.21	0.004
Non-statin only	48 (2.1%)	57 (2.5%)	1.34	0.90	2.02	0.15
Both statin+non-statin	185 (8.0%)	315 (13.6%)	1.95	1.56	2.43	<0.0001
None	1,539 (66.3%)	1,234(53.1%)	Reference
Comorbidity
Hyperlipidemia	1,254 (54.1%)	1,445 (62.2%)	1.07	0.93	1.23	0.37
Hypertension	1,046 (45.1%)	1,241 (53.5%)	1.21	1.07	1.38	0.004
Diabetes	423 (18.2%)	558 (24.0%)	1.10	0.94	1.28	0.24
Coronary artery disease	37 (1.6%)	59 (2.5%)	1.22	0.79	1.88	0.37

Adjusted for history of hypertension, hyperlipidemia, diabetes, and coronary arterial disease. CI: Confident Intervals